Hodgkin's Lymphoma

Hodgkin's lymphoma (HL) is one of oncology's most curable cancers, with overall cure rates exceeding 85–90% across all stages. Treatment has evolved from ABVD to the brentuximab vedotin–AVD (BV-AVD) combination for advanced-stage disease. Checkpoint inhibitors — nivolumab and pembrolizumab — exploit PD-L1 overexpression on Reed-Sternberg cells and have transformed relapsed/refractory management.

Approved drugs, investigational agents, and relevant clinical trials for this disease area.

Approved Drugs for Hodgkin's Lymphoma

• Doxorubicin (Adriamycin) — Anthracycline
• Bleomycin (Blenoxane) — Other
• Vinblastine (Velban) — Vinca Alkaloid
• Dacarbazine (DTIC-Dome) — Alkylating Agent
• Brentuximab Vedotin (Adcetris) — Antibody-Drug Conjugate
• Etoposide (VePesid) — Topoisomerase Inhibitor
• Cyclophosphamide (Cytoxan) — Alkylating Agent
• Vincristine (Oncovin) — Vinca Alkaloid
• Procarbazine (Matulane) — Alkylating Agent
• Nivolumab (Opdivo) — Checkpoint Inhibitor
• Pembrolizumab (Keytruda) — Checkpoint Inhibitor
• Bendamustine (Treanda) — Alkylating Agent